title: Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease.
abstract: METHODS
  Four hospitals in China.
  
  
  OBJECTIVE
  To evaluate the clinical efficacy and safety of using bicyclol in conjunction with glucurolactone in preventing drug-induced liver injury (DILI) in tuberculosis (TB) patients suffering from underlying liver disease.
  
  
  METHODS
  A total of 240 initially treated TB patients who were healthy hepatitis B carriers or had pure steatosis were randomised into two equal groups; both received an oral glucurolactone tablet 600 mg/day (200 mg three times daily) as basic liver protection. The test group also received 75 mg/day (25 mg three times daily) bicyclol tablets orally, while the control group received no other liver protection. The incidence of liver injury in the two groups, the adjustment or termination of anti-tuberculosis chemotherapy and any adverse reactions were assessed.
  
  
  RESULTS
  The incidence rate and level of severity of liver injury and the termination rate of anti-tuberculosis treatment in the test group were lower than that of the control group (P < 0.05). The overall time of occurrence of liver injury was significantly different between the two groups (P < 0.05).
  
  
  CONCLUSIONS
  Adding bicyclol to basic liver protectants may effectively and safely prevent the occurrence of anti-tuberculosis DILI in patients with underlying liver disease, and help simplify anti-tuberculosis treatment.
authors: Beijing Chest Hospital Affiliated to Capital Medical University, Beijing, China.
authors: N-H
authors: NH
authors: Chu
authors: Tianjin Haihe Hospital, Tianjin, China.
authors: L
authors: L
authors: Li
authors: Nanjing Chest Hospital, Nanjing, China.
authors: X
authors: X
authors: Zhang
authors: Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
authors: J
authors: J
authors: Gu
authors: Beijing Chest Hospital Affiliated to Capital Medical University, Beijing, China.
authors: Y-D
authors: YD
authors: Du
authors: Beijing Chest Hospital Affiliated to Capital Medical University, Beijing, China.
authors: C
authors: C
authors: Cai
authors: Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
authors: H-P
authors: HP
authors: Xiao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control*; D002681:China; D005234:Fatty Liver / Q000188:drug therapy; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D001713:Biphenyl Compounds; C477843:bicyclol